December 3, 2021

Dyne Therapeutics Announced Submission of IND Application to Initiate Clinical Trial of DYNE-251

Dyne Therapeutics, Inc. announced yesterday the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy…

Learn More

October 7, 2021

Dyne Therapeutics Presents New Preclinical Data on the Potential of FORCE Platform to Address the Genetic Basis of Duchenne

Dyne Therapeutics presents new preclinical data on the potential of FORCE platform to address the genetic basis of Duchenne. Dyne Therapeutics recently released new preclinical data from their Duchenne muscular dystrophy program, which was initially…

Learn More

April 7, 2021

WATCH: Transforming the Treatment Paradigm with Dyne Therapeutics (Webinar Recording)

Dyne Therapeutics joined Parent Project Muscular Dystrophy (PPMD) for a webinar on March 31, 2021 to provide an overview of the company’s mission, its novel FORCE platform designed to revolutionize drug delivery to muscle, and…

Learn More